At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
Vytorin +1 moredrug
Likely dose
Vytorin 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects
In Brief
A clinical study evaluating Vytorin and Placebo for Inflammation. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This study focuses on the use of Vytorin to study inflammatory markers in subjects with normal cholesterol.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation
CountriesUnited States
CollaboratorsKaleida Health
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2011
First PostedAug 2011
Primary CompletionJul 2015
Study CompletionJul 2016
TodayJul 2026
First PostedAug 19, 2011
Enrollment StartMay 1, 2011
Primary CompletionJul 1, 2015
Study CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 14.9 years ago
Interventions
Vytorindrug
Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin) for 6 weeks
Placebodrug
Placebo treatment for 6 weeks